Prescription Dry Eye Medications

When artificial tears are not enough

Preservative-free artificial tears can dilute inflammatory mediators and provide short-term symptom relief, but they do not address the underlying drivers of moderate to severe dry eye disease (DED). In many patients, DED behaves as a chronic, multifactorial inflammatory condition affecting the lacrimal functional unit. Prescription therapy aims to reduce surface inflammation, restore tear homeostasis, and support long-term ocular surface stability, in parallel with lid hygiene, environmental modifications, and systemic workup when indicated.

Identify the dominant mechanism before prescribing

DED management is most effective when it is mechanism-based. Document whether signs and symptoms point primarily to aqueous deficiency (reduced tear production, low Schirmer scores, Sjögren suspicion), evaporative disease from meibomian gland dysfunction (MGD) (lid margin changes, rapid TBUT, meibography loss), or a mixed picture. Most moderate to severe patients have overlap, so treatment plans often layer an anti-inflammatory maintenance drop with targeted evaporative support, eyelid therapy, and practical habit changes. The dry eye testing reference page provides Schirmer, TBUT, and phenol red thread normal values and severity cutoffs to support this assessment.

Immunomodulators: the foundation of long-term Rx therapy

Topical immunomodulators are the pharmacologic backbone for moderate to severe aqueous-deficient or mixed DED. They down-regulate T-cell mediated inflammation affecting the lacrimal functional unit and ocular surface.

• Cyclosporine 0.05% (Restasis): The original topical calcineurin inhibitor for DED. Reduces T-cell activation and cytokine release, with the goal of improving basal tear production and surface integrity. Clinical improvement is gradual; counsel patients that meaningful change typically takes 3–6 months of consistent twice-daily use. The most common side effect is burning on instillation, which often improves as the surface heals.
• Cyclosporine 0.09% (Cequa): A higher concentration cyclosporine using nanomicellar technology for improved corneal penetration. Same mechanism as Restasis but may achieve therapeutic tissue levels more effectively. Also dosed twice daily.
• Lifitegrast 5% (Xiidra): An LFA-1 antagonist that blocks T-cell adhesion and activation through a different pathway than cyclosporine. Many patients report symptom improvement earlier than with cyclosporine, sometimes within 2–4 weeks, though sustained benefit depends on regular ongoing dosing. Dysgeusia (altered taste) is a common side effect.

Choice between agents is guided by symptom profile, surface findings, prior response, tolerability, insurance coverage, and patient preference. There is rarely a single best option for every patient, and switching between agents is reasonable when the first choice is not tolerated or not effective after a fair trial.

Evaporative disease and MGD-targeted therapy

In evaporative DED driven by MGD, improving the lipid layer is central. Lid hygiene, warm compresses, in-office thermal expression (LipiFlow, iLux, TearCare), and IPL for associated rosacea are commonly used alongside pharmacologic therapy.

Perfluorohexyloctane (Miebo): A water-free, preservative-free drop that spreads across the tear film to reduce evaporative loss. It is positioned as an adjunct for DED associated with MGD rather than a replacement for anti-inflammatory therapy when inflammation or aqueous deficiency is also present. It does not contain water, so it does not dilute the tear film or wash out other drops.

Cyclosporine 0.1% ophthalmic solution (Vevye): A newer cyclosporine formulation in a water-free vehicle that is preservative-free and dosed twice daily. The water-free delivery may improve comfort and bioavailability for some patients.

Varenicline nasal spray (Tyrvaya): a different route

Varenicline 0.03 mg nasal spray (Tyrvaya) is a cholinergic agonist that stimulates the trigeminal parasympathetic pathway to increase basal tear production. It is administered as one spray in each nostril twice daily. Because it works via the nasal mucosa rather than the ocular surface, it avoids the instillation discomfort and preservative exposure of topical drops. The most common side effect is sneezing. Tyrvaya can be used alongside topical immunomodulators and is a useful option for patients who cannot tolerate topical drops, have significant ocular surface disease that makes drop instillation painful, or prefer a non-drop approach to tear augmentation.

Short-term steroid induction and flare management

Because immunomodulators act over weeks to months, many clinicians use a brief course of a soft topical steroid (for example, loteprednol or fluorometholone) as induction when starting long-term therapy or during symptomatic flares. A short taper can reduce surface inflammation quickly, improve comfort, and make the maintenance drop easier to tolerate. As with any steroid, IOP monitoring and clear duration/taper instructions apply. See the steroids page for potency selection and taper guidance.

Escalation: punctal plugs, serum tears, and systemic workup

When topical therapy alone is insufficient, additional measures can be layered in:

• Punctal plugs: Silicone or collagen plugs placed in the lower (and sometimes upper) puncta to reduce tear drainage and increase dwell time. They are most useful in aqueous-deficient DED. Ensure that surface inflammation is reasonably controlled before plugging, as retaining inflammatory tears on the surface can worsen symptoms. Collagen plugs dissolve in days to weeks and serve as a therapeutic trial before committing to semi-permanent silicone plugs.
• Autologous serum tears: Custom-prepared from the patient's own blood, these contain growth factors and anti-inflammatory mediators that support epithelial healing in severe or refractory DED, neurotrophic keratopathy, and persistent epithelial defects. Preparation requires coordination with a compounding lab or blood bank.
• Systemic workup: Patients with severe aqueous deficiency, bilateral presentation, or associated systemic symptoms (dry mouth, joint pain, fatigue) should be evaluated for Sjögren syndrome and other autoimmune conditions. Early rheumatologic referral and serologic testing (anti-SSA/Ro, anti-SSB/La, ANA, RF) can identify treatable systemic disease and guide long-term management.

Follow-up, realistic timelines, and adherence support

Prescription drops work best within a structured plan with documented baseline signs and scheduled follow-up. Set expectations up front: immunomodulators require weeks to months for full effect, so supportive measures (preservative-free tears, lid therapy, and environmental changes) remain important during the ramp-up period. Treatment can be escalated or simplified as the ocular surface stabilizes. Early discontinuation due to unmet expectations is the most common reason for treatment failure, so revisiting the timeline at each follow-up reinforces adherence.